Associated Papers
Genomic insights and therapeutic efficacy of PARP inhibitors in a high-LOH patient-derived xenograft from malignant transformation of ovarian teratoma.
Nakagawa A et al.
Biochemical and Biophysical Research Communications, 2025
Case Report: FAP+ fibroblasts and SPP1+ macrophages in SMARCA2-deficient while SMARCA4-preserved poorly differentiated lung adenocarcinoma: two case reports and multi-omics analysis.
Wang Z et al.
Frontiers in Immunology, 2025
Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.
Lin Y et al.
Frontiers in Oncology, 2024
38803537 (PubMed )
Supplement: Table_1.xlsx › Table_S4
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.
Wallen ZD et al.
Frontiers in Oncology, 2024
39664186 (PubMed )
Supplement: Table2.xlsx › Supplementary_Table_2
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
39703851 (PubMed )
Supplement: DataSheet2.xlsx › Supplemental_data
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M et al.
Nature Communications, 2022
36071033 (PubMed )
Supplement: 41467_2022_32828_MOESM4_ESM.xlsx › Fig_2A_and_Table_S4
Noninvasive prenatal testing of hereditary colorectal cancer syndromes using cell-free DNA in maternal plasma.
Wang Y et al.
Prenatal Diagnosis, 2022
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment.
Frank MS et al.
Cancers, 2021
35008297 (PubMed )
Supplement: cancers-14-00132-s001.zip › Supplementary_Table_S1.xlsx › Overview_ver2
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Suzuki M et al.
Translational Lung Cancer Research, 2021
33889510 (PubMed )
Supplement: tlcr-10-03-1292-supplementary.pdf
Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.
Zhang S et al.
Frontiers in Oncology, 2021
34221970 (PubMed )
Supplement: Table_3.xlsx › Supplementary_Table_S3
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.
Mateo L et al.
Genome Medicine, 2020
32907621 (PubMed )
Supplement: 13073_2020_774_MOESM1_ESM.zip › SupplementaryTables › TableS5.xlsx › Cancer_Biomarkers
Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institution.
Heeke S et al.
Journal of Translational Medicine, 2020
32066459 (PubMed )
Supplement: 12967_2020_2259_MOESM2_ESM.xlsx › Liquid_Biopsy
An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer.
Haynes BC et al.
Translational Oncology, 2019
30981944 (PubMed )
Supplement: mmc1.xlsx › S3
A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.
Demuth C et al.
Oncotarget, 2018
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
Winther-Larsen A et al.
British Journal of Cancer, 2017
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N et al.
Oncotarget, 2017
26625312 (PubMed )
Supplement: oncotarget-08-23831-s002.xls › Feuil1
Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
Kaderbhai CG et al.
Oncotarget, 2016
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.
Sanchez-Cespedes M
Oncogene, 2007
Prevalence and specificity of LKB1 genetic alterations in lung cancers.
Matsumoto S et al.
Oncogene, 2007
Select a paper to view details